U.S. Venture Partners — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Adaptive provides a cloud cost optimization platform that detects, remediates, and prevents "shadow waste" and inefficiencies across multi-cloud, Kubernetes, AI platforms, data cloud, and code.
AI & Machine LearningCloud ComputingDeveloper Tools
Aviv Revach(Founder)Eyal Brosh(Founder)
Co-investorsForgePoint CapitalLaunchpad CapitalNew Era Capital PartnersUS Venture PartnersNew Era CapitalPitango+1 more
Cagent Vascular develops endovascular medical devices, including the Serranator PTA Serration Balloon Catheter, for the treatment of vascular disease.
HardwareHealthtechMedical DevicesWayne, US
Brian Walsh(Chairman & CEO)inPeter Johansson(Chief Quality & Compliance Officer, VP Engineering)inPaul Wilson(Chief Commercial Officer)inMatt Condron(SVP of Operations)inCorey Latanision(SVP of Marketing & International Sales)inPeter Schneider(Chief Medical Advisor, Co-Founder)
Co-investorsUS Venture PartnersAstoria Health Investors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.